Biomed Industries Announces Phase 3 Trials of NA-931 Targeting Durable Weight Loss & Lean-Mass Preservation at JPM Week

Biomed Industries, Inc. Announces Two NA-931 Phase 3 Trials, Targeting Durable Weight Loss & Lean-Mass Preservation ...
Nasdaq

Orchestra BioMed Receives FDA Breakthrough Device Designation for Atrioventricular Interval Modulation Therapy to Address Uncontrolled Hypertension

Orchestra BioMed has announced that the FDA has granted Breakthrough Device Designation for its atrioventricular interval modulation (AVIM) therapy, aimed at treating over 7.7 million U.S. patients ...
Business Wire

BioMed Realty Celebrates 20 Years of Delivering Mission-Critical Life Science Real Estate

SAN DIEGO--(BUSINESS WIRE)--BioMed Realty, a leading provider of real estate solutions to the life science and technology industries, today announced the celebration of the Company’s 20th anniversary.
Seeking Alpha

Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy

Breakthrough Device Designation (“BDD”) applies to an estimated U.S. population of over 7.7 million patients with uncontrolled hypertension and increased cardiovascular risk BDD also encompasses ...
Business Wire

BioMed Realty Appoints Ankit Patel as Executive Vice President and Chief Financial Officer

Mr. Patel brings strategic and financial leadership through strengths in financial planning and analysis, capital markets, and mergers and acquisitions in the healthcare real estate sector. SAN DIEGO- ...
Nasdaq

Mainz Biomed Secures Public Funding from ISB for Pancreatic Cancer Early Detection Project

Mainz Biomed N.V., a molecular genetics diagnostic company focused on early cancer detection, announced that its pancreatic cancer project will receive public funding from the Investitions- und ...